Moderna (MRNA) President Stephen Hoge Sells $8.6M of Stock

Moderna, Inc. (NasdaqGS: MRNA) President Stephen Hoge parted with 39,145 shares of the biotechnology company on October 15, 2026, according to a Form 4 filing with the Securities and Exchange Commission.

Inside Stephen Hoge's Moderna Trade

The pre-arranged transaction was executed at an average price of $220.72 per share, bringing the total value of the sale to approximately $8.64 million. Following the transaction, the executive retains a remaining stake in the Cambridge, Massachusetts-based vaccine maker. The stock closed at $236.50 on the day of the sale.

Other Institutional Activity in Moderna

FMR, LLC grew its holdings by 6,188,477 shares, ending with 51,859,891 shares worth about $11.31 billion. Blackrock Inc. added 963,178 shares to finish with 30,599,409 shares valued at roughly $6.67 billion. Vanguard Capital Management LLC increased its position by 336,227 shares to hold 23,208,792 shares worth about $5.06 billion. Capital World Investors boosted its stake by 3,578,829 shares to 22,276,996 shares valued at $4.86 billion. Meanwhile, Baillie Gifford & Co trimmed its holdings by 1,778,708 shares, leaving it with 18,206,778 shares worth about $3.97 billion.

Moderna, Inc. Stock Down 3.7%

Shares recently traded around $218.00, down about 7.8% since the transaction date when the stock closed at $236.50. The equity sits well above its 50-day moving average of $148.05 and its 200-day moving average of $75.43. The 52-week trading range spans from a low of $22.28 to a high of $242.29.

Recent Earnings

For the trailing twelve months, Moderna reported revenue of $2.23 billion. The firm posted a net margin of -141.4% alongside a return on equity of -39.0%. The company's next earnings report is scheduled for release on November 6, 2026.

Insider Buying and Selling at Moderna, Inc.

Chief Executive Officer Stephane J. Bancel disposed of 499,246 shares valued at $28.72 million on August 5, 2026. Officer Shannon Thyme Klinger sold 3,471 shares at $139.95 apiece on September 1, 2026, totaling $485,766. Chief Financial Officer James M. Mock unloaded 34,836 shares at $134.49 each on September 10, 2026, for a total of $4.69 million. Stephen Hoge previously parted with 80,575 shares valued at $11.69 million on September 15, 2026.

Analysts Set New Price Targets

On August 28, 2026, Argus Research upgraded the stock to a buy rating with a $180.00 price target. Rothschild & Co downgraded the stock to a sell rating with a $81.00 price target on September 3, 2026. Citigroup lowered its rating to sell with a $80.00 price target on September 30, 2026. Morgan Stanley maintained an equal-weight rating and set a $95.00 price target on October 7, 2026. Goldman Sachs maintained a neutral rating with a $137.00 price target on October 15, 2026. Overall, the stock carries a hold consensus from 18 analysts with a mean target price of $123.61.

About Moderna

Moderna, Inc. is a biotechnology enterprise focused on creating messenger RNA medicines. The firm develops vaccines and therapeutics designed to address infectious diseases, immuno-oncology, and rare conditions. Its portfolio centers on advanced nucleic acid technology platforms originating out of its headquarters in Cambridge.

Bottom Line

Investors will look to the upcoming earnings release on November 6, 2026, for updates on product sales and pipeline developments. Executive transactions remain subject to pre-arranged trading plans under SEC guidelines.